Join our daily newsletter At The Bell to receive exclusive market insights
- Little Green Pharma (LGP) has delivered its first shipment of medicinal cannabis oil to France, ahead of the upcoming national trial
- Earlier this year, LGP won a government tender to be the primary supplier of medicinal cannabis oils for a national trial in France
- The two-year trial will test the efficacy, safety and quality of medicinal cannabis in up to 3000 patients
- Notably, if this trial is successful it may lead to the legalisation of medicinal cannabis in France
- The cannabis oils are expected to be made available to trial patients later this month
- On the market this afternoon, LGP is up 2.34 per cent and is trading at 65.5 cents per share
Little Green Pharma (LGP) has delivered its first shipment of medicinal cannabis oil to France.
The products have been shipped for the French national medicinal cannabis trial.
In January, LGP won a government tender to be the primary supplier of medicinal cannabis oils for a national trial in France. The two-year trial will test the efficacy, safety and quality of medicinal cannabis in up to 3000 patients.
Notably, if this trial is successful it may lead to the legalisation of medicinal cannabis in France.
The cannabis oils are expected to be made available to trial patients later this month.
Being the primary supplier of this trial, LGP is following its strategy of growing and holding significant market share in key European growth markets, including Germany, the U.K. and France.
Additionally, earlier this week, the company completed its $5 million share purchase plan to help speed up sales and marketing efforts in both Australia and overseas.
On the market this afternoon, LGP is up 2.34 per cent and is trading at 65.5 cents per share at 12:44 pm AEDT.
